Please provide your email address to receive an email when new articles are posted on . Of adults receiving elegrobart every 4 weeks, 50% had a decrease in proptosis at 24 weeks compared with 15% of ...
Findings showed a significantly greater proptosis responder rate in patients treated with elegrobart Q4W vs placebo (54% vs 18%; P .0001). Topline data were announced from a phase 3 trial evaluating ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 37-year-old white woman 2 weeks postpartum from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results